Atlas Trials

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Clinical trial NCT04454437 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04454437
Sponsor
Gilead Sciences
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Triple-negative Breast Cancer
Start date
2020-10-23
Primary completion
2021-08-06
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.